证券代码：600211 证券简称：西藏药业 公告编号：2025-021 ●本次担保是否有反担保：被担保全资子公司生物医药向本公司提供反担保。 ●对外担保逾期的累计数量：无。 ●特别风险提示：本次被担保对象生物医药为资产负债率超过 70%的公司，敬请投资 者注意相关风险。 一、担保情况概述 （一）担保基本情况 西藏诺迪康药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：本公司全资子公司西藏诺迪康生物医药销售有限公司（以下简称"生 物医药"）；本次担保不存在关联担保。 ●本次担保金额及已实际为其提供的担保余额：近期我公司为生物医药提供担保金额 为人民币 4,100 万元。截至本公告日，我公司已实际为生物医药提供的担保余额为人民币 19,100 万元。 公司名称：西藏诺迪康生物医药销售有限公司 统一社会信用代码：91540091MABUYT4X4H 成立日期：2022-7-25 注册资本：2800 万元 具体内容详见公司于 2025 年 3 月 15 ...

Group 1 - China State Construction signed new contracts totaling 1.52 trillion yuan from January to April, representing a year-on-year increase of 2.8% [1] - Yongpu Medical's subsidiary obtained a medical device business license valid until May 7, 2030, allowing it to engage in medical device retail and wholesale [1] - Ningbo Maritime received a government subsidy of 4.42 million yuan, which will impact its net profit for the fiscal year 2025 [1] Group 2 - Mingpu Optoelectronics obtained a patent for a magnetic powder core and its preparation method, enhancing its capabilities in magnetic materials technology [1] - Digital Zhitong plans to establish a wholly-owned subsidiary in Beijing with a registered capital of 5 million yuan [1] - Zhongmin Energy's shareholder plans to reduce its stake by up to 0.28% of the company's total shares [1][6] Group 3 - Tunnel Holdings' controlling shareholder intends to increase its stake in the company by investing between 250 million to 500 million yuan [1] - China Telecom appointed Liu Guiqing as the new President and COO [1] - Datang Power completed the issuance of 3 billion yuan in medium-term notes, with proceeds aimed at repaying debt and supplementing working capital [1] Group 4 - *ST Weihai won a bid for a flood control project worth 182 million yuan, accounting for 7.35% of its audited revenue for 2024 [1] - Huijin Tong announced a cash dividend of 0.0868 yuan per share, totaling 29.44 million yuan [1] - Xinkai Energy's shareholders plan to reduce their holdings by a combined total of 4% of the company's shares [1][39] Group 5 - Xinhuan Group's subsidiary won a 1.02 billion yuan nuclear power project contract [1] - Southern Airlines reported a 12.14% year-on-year increase in passenger turnover for April [1] - Xinjiang Torch plans to acquire 100% equity of Yushan Litai for 125 million yuan [1]

证券代码：600211 证券简称：西藏药业 公告编号：2025-020 西藏诺迪康药业股份有限公司 关于全资子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司全资子公司成都诺迪康生物制药有限公司于近日收到国家药品监督管理局颁发的 《药品补充申请批准通知书》，现将相关情况公告如下： 一、《药品补充申请批准通知书》的主要内容 受理号：CYSB2300200 通知书编号：2025B02098 药品通用名称：注射用重组人脑利钠肽 商品名称：新活素 剂型：注射剂 包装规格：1 瓶/盒；2 瓶/盒 药品注册标准编号：YBS00272025 申请内容：药学研究信息：1、在原车间紧邻的综合空闲厂房内，按原产线的生产规模及 生产工艺复制了一条冻干生产线（冻干车间 B 线）；2、在质量部四楼新建生物活性实验室。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事 项符合药品注册的有关要求，批准本品如下补充申请事项：1、在原车间紧邻的综合空闲厂房 内，按原产线的生产规模及生产工艺 ...

Industry Overview - The vaccine industry is experiencing a significant decline in 2024 and the first quarter of 2025, with total revenue dropping from 1,637 billion in 2023 to 1,283 billion in 2024, marking a year-on-year decrease of 21.6%, the first negative growth in five years [1] - Net profit in the industry has decreased from a peak of 309 billion in 2021 to 120 billion in 2024, a reduction of 61%, with profit margins declining from 21.7% in 2021 to 9.4% in 2024, indicating increased cost pressures [1] Company Performance - Leading companies show significant performance divergence; TianTan Bio and Tibet Pharmaceutical have reported growth, with TianTan Bio achieving 60 billion in revenue for 2024, a 17.6% increase, and a net profit of 15 billion, up 36.4% [3] - In contrast, Zhifei Biological and Wantai Biological have faced substantial declines due to intensified competition in the HPV vaccine market, with Zhifei's revenue plummeting from 529 billion in 2023 to 260 billion in 2024, a 50.8% drop, and net profit falling from 80 billion to 20 billion, a 75% decrease [3] - Wantai Biological's net profit decreased from 47 billion in 2022 to approximately 1 billion in 2024, with a drop in gross margin from 89% to 66% [3] Cost and Profitability Trends - The median sales expense ratio in the industry has increased from 48% in 2020 to 58% in 2024, with over half of the companies exceeding a 50% expense ratio [3] - Changchun High-tech's sales expense ratio rose from 44% in 2023 to 57% in 2024, with net profit margin declining from 31% to 18.7% [3] - Kanghua Biological maintained a high gross margin of 93%, but its expense ratio increased from 47% to 54%, leading to a decrease in net profit margin from 33% to 21% [3] Vaccine Approval Trends - In 2024, most vaccine varieties saw a decline in batch approvals, with Zhifei Biological's HPV vaccines experiencing significant drops in approvals, including a 95% decrease for the four-valent HPV vaccine [4] - The first quarter of 2025 showed a mixed performance in vaccine approvals, with the recombinant herpes vaccine seeing a 54% decline in batch approvals, while the two-valent HPV vaccine saw a 367% increase [4] Specific Vaccine Performance - Rabies vaccines showed good overall approval growth, with Vero cell rabies vaccines achieving 199 batch approvals, a 24% increase [5] - The flu vaccine approvals in the first quarter of 2025 saw a significant increase of 500%, with the three-valent flu vaccine experiencing a 1300% increase in approvals [5] - The 13-valent pneumonia vaccine approvals remained stable, while the 23-valent pneumonia vaccine saw a 71% decline [5]

(本版专题数据由证券时报中心数据库提供) 内需市场一头连着经济发展，一头连着社会民生，是经济发展的重要依托。 2025年政府工作报告将"大力提振消费、提高投资效益，全方位扩大国内需求"列为今年政府工作十项任 务之首，并围绕"大力提振消费"作出了具体工作部署，提出要"实施提振消费专项行动，制定提升消费 能力、增加优质供给、改善消费环境专项措施，释放多样化、差异化消费潜力，推动消费提质升级"。 今年以来，一系列扩内需促消费政策发力显效，做强国内大循环，进一步释放我国超大规模市场活力。 在一季度实现"开门红"后，多地抓紧部署二季度经济工作重点，明确进一步聚焦提振内需，加快释放政 策效能。 广东明确，大力提振消费需求，深入实施提振消费专项行动，推动消费品以旧换新政策惠及领域进一步 延伸拓展，持续放大撬动效应；适度加大消费补贴和政府采购力度，促进广货国货消费、新型消费、入 境消费、公共消费等，不断挖掘消费增量，激发消费活力。 紧随其后的是达仁堂（600329），滚动市盈率为10.3倍。公司2024年归母净利润为22.3亿元，同比增长 125.94%，拟向全体股东每10股派发现金红利12.80元(含税)。市盈率较低的还有 ...

Group 1 - The core point of the article highlights that the current dividend distribution season has seen 7 companies implementing their distribution plans, with a total of 1695 companies proposing distribution plans for the 2024 fiscal year [1] - In the context of regulatory encouragement for cash dividends, 1692 out of the 1695 companies have included cash dividends in their plans, amounting to a total cash distribution of 1.22 trillion yuan [1] - The article emphasizes two important dates for investors focused on dividends: the ex-dividend date and the record date, with 30 companies having already implemented their distribution plans [1] Group 2 - Among the 7 companies with a record date today, the largest cash distribution is from Ningde Times, which proposes a cash dividend of 45.53 yuan per 10 shares, followed by Tibet Pharmaceutical and汤臣倍健 with 7.28 yuan and 3.60 yuan respectively [1][2] - The stock performance of the companies on the record date shows that the highest increase over the past 5 days is from Ultrasonic Electronics, with a cumulative increase of 7.41%, while other notable performers include Daodaquan and汤臣倍健 [2] - A detailed table lists the upcoming dividend distributions, including the cash distribution per 10 shares and the latest closing prices for each company [2]

Investment Rating - The report does not specify a clear investment rating for the company [1][6]. Core Views - The company's performance in 2024 met expectations, with a total revenue of 28.1 billion yuan, a year-on-year decrease of 10.5%, and a net profit attributable to the parent company of 10.5 billion yuan, an increase of 31.3% [6][9]. - The sales of the main product, New Huo Su, experienced a decline, with a total sales revenue of 24.3 billion yuan, down 13.6% year-on-year [6][9]. - The company plans to continue high cash dividends, proposing a cash dividend of 0.728 yuan per share, totaling 630 million yuan, which accounts for 60% of the net profit attributable to shareholders [6][9]. Summary by Sections Financial Performance - Revenue for 2024 was 28.1 billion yuan, with a growth rate of -10.45% [2][9]. - Net profit attributable to the parent company was 10.5 billion yuan, with a growth rate of 31.26% [2][9]. - Earnings per share (EPS) for 2024 was 3.26 yuan [2][9]. - The return on equity (ROE) was 26.75% [2][9]. Future Projections - Revenue projections for 2025-2027 are 29.6 billion yuan, 33.2 billion yuan, and 37.3 billion yuan, respectively, with growth rates of 5.56%, 12.14%, and 12.26% [2][9]. - Net profit projections for 2025-2027 are 9.4 billion yuan, 10.5 billion yuan, and 11.3 billion yuan, respectively [6][9]. Product Sales Forecast - New Huo Su sales are projected to be 25.1 billion yuan in 2025, with a growth rate of 3% [8][9]. - Other product sales are expected to grow significantly, with projections of 452.8 million yuan in 2025, reflecting a growth rate of 21.1% [8][9]. Cost and Profitability - The gross profit margin for 2024 was 94.2%, with a slight decrease expected in the following years [6][9]. - The company aims to control the cost ratio to within 70% for 2025 [6][9].

●在实施权益分派的股权登记日前公司总股本发生变动的，拟维持现金派发总额不变， 相应调整每股派发金额，并将另行公告具体调整情况。 证券代码：600211 证券简称：西藏药业 公告编号：2024-041 西藏诺迪康药业股份有限公司 关于 2024 年第三季度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●每股分配比例：A 股每 10 股派发现金红利 2.62 元（含税）。 ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在权益 分派实施公告中明确。 关规定。 （二）公司第八届监事会第一次临时会议以 3 票同意，0 票反对，0 票弃权，审议通过 了《2024 年第三季度利润分配方案》。 （三）公司 2023 年年度股东大会已授权董事会在 2024 年中期和第三季度报告后，在 不影响公司正常经营和后续发展的情况下，根据实际情况适当增加现金分红频次，制定并 实施具体的现金分红方案，分红上限不超过相应期间归属于上市公司股东的净利润。故本 议案无需提交股东大会审议，董事会审议通过后即 ...

青侨阳光医药投资 - 投资思考 在过去几年里，一个印象深刻的教训，是不同时期、不同标的之间的强烈异质性。 这种异质性，既体现在同 一时期不同标的在基本面方面的剧烈分化，也体现在同一标的不同时期在股价主导逻辑上的强烈变迁。 这里的异质性，不管是基本面表现的分化和股价逻辑的变迁，放在特定时空下都有其自洽的合理性，因此 当 出现远超我们预期的事实时，所反映的未必是市场的非理性或世界的不正常，而更可能是我们的认知脱离了客 观真相，形成了局限偏颇。 跳出简单化的、平均化的、定式化的、教条化的思维模式，去重新审视客观事实 中所展现的混沌复杂和随机多变，或许能为日常投研带来新的视角，促进新的思考，形成新的认知。 1 横向视角下的分化： 在爆款思维里，寻找潜在的时代徽章 先看一下横截面上的分化。 下图是早年(2017年之前)获批上市的国产创新药，在2022年PDB样本医院的终端销售额，可以看到， 不同创新 药之间的营收差异很大 ：新活素成就了西藏药业，特比澳奠定了三生制药的基础，恩必普也为石药集团成功 打开了制剂业务的空间；但与此同时，曾经红极一时的今又生早已销声匿迹，优朋、可唯适、利卡汀、谊生泰 们苦苦挣扎在生存的边缘，就 ...

证券简称：西藏药业 证券代码：600211 编号：2024-039 西藏诺迪康药业股份有限公司 关于 2024 年半年度暨第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于 2024 年 11 月 4 日（星期一）下午 15:00-16:00 在上海证券交易所上证路演 中心（网址：http://roadshow.sseinfo.com/），以网络文字互动方式召开了公司 2024 年 半年度暨第三季度业绩说明会，现将召开情况公告如下： 一、业绩说明会召开情况 本公司于 2024 年 10 月 26 日在《中国证券报》《上海证券报》《证券时报》及上海证券 交易所网站（www.sse.com.cn）披露了《关于召开 2024 年半年度暨第三季度业绩说明会的 公告》。2024 年 11 月 4 日下午 15:00—16:00，公司董事长陈达彬先生、总经理郭远东先生、 副总经理兼董秘刘岚女士、财务总监陈俊先生、独立董事满加云先生、张宇先生、林建昆 先生出席了本次业绩说明会，并与投资者进行互动交流和 ...